摘要
目的:探讨MVP方案(丝裂霉素+长春酰胺+顺铂)介入与静脉化疗结合治疗中晚期非小细胞肺癌的疗效。方法:选取79例中晚期非小细胞肺癌患者随机分为两组,治疗组采用MVP方案经支气管动脉灌注辅加MVP方案静脉化疗,对照组采用MVP方案单纯静脉化疗,两组临床疗效及不良反应等方面临床观察。结果:治疗组37例总有效率为89.2%(33/37),对照组42例总有效率为47.6%(20/42),两种不同给药途径MVP方案的近期疗效有显著统计学差异(P<0.01),且发热、胃肠道反应、骨髓抑制不良反应亦有显著统计学意义(P<0.05)。结论:MVP方案介入与静脉化疗结合治疗中晚期非小细胞肺癌疗效高,不良反应轻。
Objective: To evaluate the efficacy of the combination therapy consisting of bronchial arterial infusion and adjuvant intravenous chemotherapy with the MVP regimen (mitomycin, vindesine and cisplatin) on intermediate or advanced non-small cell lung cancer. Methods: Seventy-nine patients with intermediate or advanced non-small cell lung cancer were divided into two groups at random. A combination therapy consisting of bronchial arterial infusion with the MVP regimen and adjuvant intravenous chemotherapy subsequent to the former with the same regimen was administered to the patients in the treatment group in contrast to intravenous chemotherapy alone with the MVP regimen in the control group, and a clinical control observation on effectiveness and adverse effects was carried out in two groups. Results: Of the 37 patients in the treatment group, the total response rate was 89.2%(33/37) compared with 47.6%(20/42) in the control group consisting of 42 patients. There was a statistically significant difference in the short term effectiveness of treatment with the MVP regimen between two variant administering approaches (P<0.01), as well as in the adverse effects of treatment, such as fever, gastrointestinal disturbance and bone marrow suppression (P<0.05). Conclusion: The combination therapy consisting of bronchial arterial infusion and adjuvant intravenous chemotherapy with the MVP regimen on intermediate or advanced non-small cell lung cancer shows more effectiveness and less adverse effect.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第10期579-581,共3页
Chinese Journal of Clinical Oncology
关键词
支气管动脉灌注
全身化疗
MVP方案
非小细胞肺癌
Bronchial Arterial Infusion Intravenous Chemotherapy MVP regimen Non-Small Cell Lung Cancer
